Gecko Biomedical, a Paris, France-based medical device company developing innovative polymers to support tissue healing, closed a €22.5m Series A2 financing round.
The round was led by Sofinnova Partners, which has become the largest investor in Gecko, with support from Bpifrance and existing investors Omnes Capital, CM-CIC Innovation and CapDecisif Management. In conjunction with the financing, Antoine Papiernik at Sofinnova Partners and Chahra Louafi at Bpifrance joined Gecko’s Board of Directors.
The company intends to use the funds to further advance the development of its platform GB-02 for cardiovascular reconstruction and beyond, and leverage its platform in novel areas including guided tissue repair and localized drug delivery.
Co-founded by Christophe Bancel and Bernard Gilly (both from the iBionext Network), Prof Jeff Karp (Harvard Medical School, Brigham and Women’s Hospital – Boston, MA, USA) and Prof Bob Langer (Massachusetts Institute of Technology – Cambridge, MA, USA) in late 2013, Gecko Biomedical is a medical device company dedicated to the development and commercialization of a biopolymers platform, with chemical and physical properties, including high viscosity, hydrophobicity and ondemand curing for precise local delivery and in situ adhesion.
Its first product (GB-02) is an innovative polymer for tissue healing, targeting cardiovascular reconstruction as an initial indication. The structure of GB-02 allows customization for various applications and tissues.
The platform has potential novel applications in other fields of tissue reconstruction, such as guided tissue repair and localized drug delivery.